ARROWSTREET CAPITAL, LIMITED PARTNERSHIP has opened a new $111.1M position in $GSK, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 12-31-2025 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $GSK.
$GSK Hedge Fund Activity
We have seen 430 institutional investors add shares of $GSK stock to their portfolio, and 439 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX removed 9,885,765 shares (-12.6%) from their portfolio in Q4 2025, for an estimated $484,797,915
- ACADIAN ASSET MANAGEMENT LLC added 6,175,701 shares (+221.5%) to their portfolio in Q4 2025, for an estimated $302,856,377
- FMR LLC added 5,139,956 shares (+8.4%) to their portfolio in Q3 2025, for an estimated $221,840,500
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 2,265,186 shares (+inf%) to their portfolio in Q4 2025, for an estimated $111,084,721
- WELLINGTON MANAGEMENT GROUP LLP added 1,965,611 shares (+135.1%) to their portfolio in Q3 2025, for an estimated $84,835,770
- CAPITAL RESEARCH GLOBAL INVESTORS removed 1,794,427 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $87,998,700
- CLARK CAPITAL MANAGEMENT GROUP, INC. removed 1,779,776 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $76,815,132
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GSK Congressional Stock Trading
Members of Congress have traded $GSK stock 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $GSK stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$GSK Analyst Ratings
Wall Street analysts have issued reports on $GSK in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Underweight" rating on 01/06/2026
- Jefferies issued a "Buy" rating on 10/27/2025
To track analyst ratings and price targets for $GSK, check out Quiver Quantitative's $GSK forecast page.
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $GSK ticker page for more data.
